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Regulatory control, i.e. the imposition of norms by
competent authorities in order to control business and
industry, has again become the subject of public debate.
Contrary to the health care sector in general, the phar-
maceutical sector is known to be under strict normative
control. It is similarly subject to heavy legislative and
normative controls internationally. 
Times do change, however, and the need arises to re-
view the regulations and directives issued by authorities,
with regard to the contents, as well as the powers to im-
pose such control measures.  Such reviews are usually
carried out ex officio, but external pressure groups may
also make themselves heard occasionally. 
Following a complaint about the powers of the Na-
tional Agency for Medicines, Paavo Nikula, the Council
of State’s Chancellor of Justice, decided on 13 February
2001 to ask the Ministry of Social Affairs and Health to
speed up its review of the nature and extent of powers
delegated under the Medicines Act, with reference to the
new constitution. National Agency for Medicines’
(NAM) regulation 3/1999 was at issue. It contained a
prohibition on the advertising  of pharmaceuticals to the
public by pharmacies outside their regular premises. Al-
though NAM could not be said to have exceeded its
powers when issuing the regulation, the matter was sub-
ject to several interpretations, and the regulation should
be placed in abeyance pending an investigation. That is
what the National Agency for Medicines has done.
The Ministry of Social Affairs and Health has
promptly begun to investigate the matter, and a new ap-
praisal of the correct status of normative control in leg-
islation, government decrees and regulations issued by
public authorities is pending.
Especially the fundamental regulations controlling
the promoting of pharmaceuticals and the regulations
currently of normative control status, should be includ-
ed in the Medicines Act. Let us look at two cases, in
which the need to upgrade control practices is obvious,
as the present regulative status is insufficient. 
The first case concerns the prohibition on advertising
prescription medicines to the public. This prohibition is
common in Europe, and particularly in the European
Union it is quite unambiguous. In Finland, the National
Agency for Medicines has promulgated a matching reg-
ulation. Despite that, most pedestrians in Finland can
see certain prescription medicines being covertly adver-
tised in the street in posters advising consumers to ask
their physicians to prescribe the product in question.
This result of innovative thinking by the pharmaceutical
industry is clearly a contravention of the spirit of the
marketing prohibition. Stricter legislation is clearly
needed.
The other case concerns the advertising of medicines
by pharmacies outside their premises. When issuing reg-
ulation 3/1999, the key argument of the National
Agency for Medicines was that Finnish pharmacies
should retain their role of independent experts towards
the consumers. The consumer must be able to believe
that his medication needs are not dictated by the phar-
macy’s advertising campaign. A system whereby phar-
maceutical retailers are acting as marketing partners of
the pharmaceutical industry does not fit in with the pre-
sent objectives of our health care policy.  Seeing that
pharmacies appear to have conflicting views on the ba-
sic nature of their business, regulations must obviously
be spelt out more clearly. In his resolution, the Chancel-
lor of Justice stated that the objective of NAM’s regula-
tion was in agreement with Section 1 of the Medicines
Act.
There are dozens of authorisations for normative
control in the legislation on pharmaceuticals.
In addition to adjusting the level at which regula-
tions may be issued to match the new constitution, it is
possible that other reasons for reviewing the contents of
regulations or legislation in some way are discovered.
From NAM’s viewpoint, it is important that normative
control promotes the safety of medicines on the one
hand, and the rational and safe usage medicines on the
other hand.
Hannes Wahlroos
DIRECTOR GENERAL
National Agency for Medicines 
Norms to their rightful status
Editorial
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The goal of prophylaxis and man-
agement of osteoporosis is preven-
tion of bone fractures.  The  corner-
stones of prophylaxis include suffi-
cient intake of calcium and vitamin
D, regular exercise and avoidance of
smoking.  These are also the main
emphases in osteoporotic patients.
In addition to treating osteoporosis,
osteoporosis medication can also be
considered for the prophylaxis of os-
teoporosis in patients whose bone
mineral density approaches the
severity of osteoporosis at a  stage
of life when the bone condition is
likely to deteriorate (menopause,
long-term treatment with  corticos-
teroids).
Vitamin D
Finns have a surprisingly low level
of vitamin D.  The deficiency of vit-
amin D in the elderly has been es-
tablished but adolescents appear to
be a new risk group.  The vitamin D
level is best reflected by the serum
vitamin 25(OH)D concentration.
When the concentration is de-
creased, the serum calcium level is
reduced, which causes increased
parathyroid hormone (PTH) secre-
tion and serum PTH concentration.
The parathyroid hormone  stimu-
lates bone change, especially in the
cortical bone, and this exposes the
patient to hip fracture.  In popula-
tion studies the PTH level was ele-
vated when serum 25(OH)D con-
centration was reduced to a level of
37 nmol/l.  This, which  is nowa-
days considered the minimum level
of vitamin D concentration, is dis-
tinctly higher than the minimum lev-
el of Finnish reference values of 20
nmol/l.  In October 1998, vitamin
25(OH)D concentrations below the
minimum level were found in two
out of three patients (average age of
63 years) in Finnish hospital internal
medicine wards and in two out of
five patients (average age of 44
years)  in out-patient wards.  In win-
ter 1997, a similar deficiency in vita-
min D was found in two out of
three girls in south-western Finland
and, according to our own yet un-
published findings, in two out of
three Finnish conscripts at the begin-
ning of summer 2000.
Several studies have shown that
co-administration of calcium and vi-
tamin D can prevent hip fractures
and other fractures.  Co-administra-
tion of calcium and vitamin D is im-
portant.  No benefit was found in
the use of vitamin D alone.  The
daily intake of calcium should total
1–1.5 grams and vitamin D
400–800 Units.  Irrespective of age,
Finns should consider a daily vita-
min D supplement of 400 Units dur-
ing winter time.  The elderly, whose
outdoor pursuits are infrequent, can
safely be given daily doses of 800
Units all the year round;  intoxica-
tion has only developed with doses
amounting to 10,000 Units or more.
It should be recognised that
placebo groups in osteoporosis drug
studies have as a rule also received
calcium and vitamin D.  If a specific
osteoporosis medication has de-
creased bone fractures more than
the placebo, the benefit has in that
case been  additional to that from
the co-administration of calcium
and vitamin D.
When should an actual osteo-
porosis drug be introduced?
Indications  for pharmacological
treatment of osteoporosis include
past history of osteoporotic fracture
or bone mineral density equal to
that of the osteoporotic stage in the
lumbar vertebrae or femoral neck
[bone mineral density 2.5 standard
deviations (= about 25%), or more,
below the average bone mineral den-
sity in young adults = so-called T-
score below ≤ – 2.5].  The decision
of whether to resort to treatment is
influenced by the age, overall situa-
tion, other illnesses and medical
treatment of the patient.
Poor availability of density mea-
surements is a problem in the diag-
nosis of osteoporosis.  Health cen-
tres should afford their doctors the
opportunity to refer their patients
for density measurement which can
be either bought from a hospital or
from the private sector.  The unit
carrying out the measurement will
then provide an account of the ex-
amination which the patient takes to
his or her own doctor.  The exami-
nation can be bought directly from a
hospital without an unnecessary and
costly appointment at an outpatient
department.  Strict criteria could be
applied to referrals  for treatment.
The first patients to undergo exami-
nations should be women over 65
years of age with a history of frac-
tures (= confirmation of diagnosis of
osteoporosis) and who do not use
estrogen treatment or other drugs
protective against osteoporosis.  The
first diagnostic examination is the
most important and follow-up ex-
aminations are not absolutely neces-
sary.
Which drug?
Osteoporosis should be treated with
drugs which have been shown to
prevent bone fractures in controlled
Matti J. Välimäki
ASSOCIATE PROFESSOR, CHIEF PHYSICIAN
Dept of Endocrinology
Helsinki University Central Hospital
Drugs for osteoporosis  - when and which one?
Summary 
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clinical studies (table).  On-going
placebo-controlled studies have  in-
dicated that vertebral fractures are
preventable by several drugs, but hip
fractures only by alendronate and
risedronate in addition to calcium
and vitamin D.  Proof of prevention
of hip fractures in estrogen therapy
is  based only on control and cohort
studies. The choice is governed by
the price and efficacy of the drug,
site of the osteoporosis (treatment of
osteoporosis of the upper  femur on-
ly with  drugs which have prevented
hip fractures) and any other benefits
and adverse effects of the drug
which are considered in the total as-
sessment of the patient’s situation.
Estrogen treatment is  justified by
symptoms of menopause.  A history
of breast cancer in the patient, in the
family or as a  phantom in the mind
may deter estrogen treatment and
justify the use of bisphosphonates
(alendronate, etidronate, rise-
dronate) or raloxifene of the selec-
tive estrogen receptor modulator
(SERM) group which in a 5-year
follow-up has prevented the occur-
rence of breast cancer.  Mild hyper-
cholesterolaemia justifies estrogen
treatment and the use of raloxifene,
both of which reduce serum total
cholesterol and LDL cholesterol by
10–15%.  Problems associated with
menstruation constitute a con-
traindication for estrogen treatment
and support the use of biphospho-
nates, or raloxifene which has no ef-
fect on the endometrium, causes no
menstrual bleeding and does not re-
quire progestine supplements. The
analgesic properties of calcitonin are
useful in the context of vertebral
crush fractures.
Even though placebo-controlled
studies do not indicate that biphos-
phonates cause gastro-intestinal irri-
tability, these drugs are nevertheless
often associated with various ali-
mentary tract symptoms.  Patients
with a history of abdominal disor-
ders are usually excluded from clini-
cal studies, which may explain dif-
ferences in result in practical experi-
ence.  Raloxifene will not prevent
hot flushes and its use may be asso-
ciated with cramps. 
In association with painful verte-
bral fractures calcitonin can  readily
be combined with another osteo-
porosis drug.  According to two
studies, the combination of estrogen
and alendronate or etidronate is
more effective than either of the
drugs alone, and the effect of alen-
dronate alone is likely to be superior
to that of estrogen.
Osteoporosis in men
Diagnosis of osteoporosis in men
should be followed by measurement
of serum testosterone.  If  the level
of testosterone is reduced, replace-
ment therapy should be started.  It
should be borne in mind that men
on long-term corticosteroid therapy
may need testosterone replacement
therapy because corticosteroids re-
duce the concentration of testo-
sterone.  Idiopathic osteoporosis in
men is treated with calcitonin and
biphosphonates.  Among the above
mentioned drugs only alendronate
entitles  men to full refund in the
Finnish health insurance scheme.
Even though only alendronate has
been proved  to reduce fractures in
osteoporotic men so far, etidronate
and risedronate should also entitle
men to full refund of medical costs.
Their effect when compared with al-
endronate has been very similar to
that in studies carried out on
women, and it is hard to imagine
why the response  of the male skele-
tal system  should vary from one
biphosphonate to another.  Alterna-
tives in the treatment of osteoporot-
ic men are also needed in case, for
instance, alendronate should for
some reason prove  inappropriate.
Secondary prevention should be
the starting point
Cholesterol-lowering medication is
the most cost-effective treatment in
secondary prevention, i.e. those with
coronary artery disease would re-
ceive the greatest benefit from it.
The same is most likely to apply al-
so in  the treatment of osteoporosis.
The biggest benefit would be re-
ceived by those with a history of
fractures, and they should be the
first ones to be covered by the treat-
ment.  The first fracture is predictive
of another occurring.  After the first
vertebral fracture, the risk of anoth-
er vertebral fracture will be five-fold
and that of a hip fracture will be
double.  After a second vertebral
fracture, the risk of a later vertebral
fracture is 11-fold.  After a wrist
fracture, the risk of a hip fracture is
double and after a hip fracture the
risk of any fracture is 2–5-fold.
Fractures can be prevented with new
drugs in those with a history of frac-
tures.  Placebo-controlled studies of
patients who have sustained a verte-
bral fracture showed that the occur-
rence of a new vertebral fracture
was reduced by 47% with alen-
dronate, 41% with risedronate,
30–50% with raloxifene and 36%
with intranasal calcitonin when the
daily dose totalled 200 Units.  The
NNT figures (number needed to
treat) in these studies show how
many patients had to be treated dur-
ing the study in order to prevent one
patient from sustaining a fracture.
In those with a history of fractures,
the figures have been realistic and
varied between 9 and 22 in 3-year
studies.  If the criterion  for inclu-
sion in the study has only been a
mineral density level similar to that
in osteoporosis without a fracture,
the increase in figures has been
manyfold and varied between 35
and 58.  The difference is explained
by the difference in the incidence in
various placebo groups.  New frac-
tures in the placebo group among
those with a history of fractures oc-
curred in 15–26% of patients during
three years, whereas the percentage
was 5–6% in patients with osteo-
porosis diagnosed on the basis of
the density criterion.
Drugs which reduced fractures
in control led tr ia ls
In the vertebrae
Estrogens
Raloxifene
Alendronate
Etidronate
Risedronate
Calcitonin (200 Units/day)
In  the hip
Alendronate
Risedronate
Calcium + vitamin D
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How can the cost-effectiveness
of treatments be improved?
In addition to those who have al-
ready sustained a fracture, the diag-
nosis and treatment of osteoporosis
should be focused on people in the
appropriate age group.  Osteoporo-
sis with consequent occurrence of
fractures increases sharply with age.
Age is an independent predictor  (=
independent of bone mineral densi-
ty) of a fracture in that its risk be-
comes 2–3 times higher with every
ten years of age.  The efficacy of
medical treatment is proven in the
elderly;  all the above studies have
been carried out in people with an
average age of 70.  Furthermore, the
cost-effectiveness of treatment is
definitely better in the elderly who,
independently of their bone condi-
tion, sustain fractures more fre-
quently than the young, in whom
fractures in fact seldom occur.
The question still remains, how-
ever, which is the most cost-effective
age to start the treatment of osteo-
porosis.  In studies where alen-
dronate and risedronate have dimin-
ished the occurrence of hip fractures
by 40-56%, the average age of sub-
jects varied between 68 and 74
years.  Due to the low incidence in
the placebo group (only 2–3%) the
NNT figures in these studies are un-
reasonably high (81–93).  Conse-
quently, it would seem that medical
treatment to prevent hip fractures
should be directed towards even
older people who sustain these frac-
tures frequently.  Sub-group analyses
in the risedronate study on  the pre-
vention of hip fractures arrived at as
good an NNT figure  as 40 during a
3-year course of treatment, when
patients of the average age of 74
years in addition to a low mineral
density at  the femoral neck (T-score
< – 3), also had at least one verte-
bral fracture.  Consequently, to im-
prove the cost-effectiveness,  suffi-
ciently old patients should be treat-
ed whose bone mineral density is  at
a level similar to that of osteoporo-
sis and who have previously had a
fracture.  The cost-effectiveness is
naturally improved by any other
beneficial extra-skeletal effects of
the drug (prevention of breast can-
cer, beneficial effect on risk factors
of cardiovascular diseases).
Treatment of the skeletal system
is not sufficient
The development of vertebral frac-
tures is to a great extent dependent
on internal risk factors, i.e. poor
bone condition.  The vertebra can
be fractured in normal everyday
routines without any external trau-
ma.  A hip fracture is a different
story.  Internal risk factors are deci-
sive in the fracture, the development
of which nevertheless usually always
requires significant external trauma.
There is a 13-fold increase in the
risk of hip fractures between the age
of 60 and 80.  Conditions which
can be treated with medication (de-
crease in mineral density, accelerat-
ed absorption of bone) explain a 4-
fold increase.  The increase  in acci-
dental falls is responsible for the
rest, the 9-fold increase.  Conse-
quently, the ultimate emphasis
should be on the prevention of  ac-
cidental falls and protection against
them.  Protection may be easier
than prevention.  A significant
Finnish study showed that the risk
of hip fractures was decreased by
60% in people using hip pads  dur-
ing a 2-year follow-up.  In order to
prevent one hip fracture, 41 people
had to wear pads for a year.  If the
NNT figure was calculated on five
years, eight people would have had
to wear pads for that period of time
to prevent one hip fracture.  The
problem at least up until now has
been treatment compliance.  About
a third of the patients refused to
wear any kind of pads and 9 of the
13 fractures in the pad group oc-
curred while the pads were in the
wardrobe.
What is to be expected 
in the future?
A 70 mg tablet of alendronate will
also be introduced on the Finnish
markets in September.  It is adminis-
tered only once weekly, in a way
similar to that of the present 10 mg
tablet which is administered once
daily.  Once-weekly administrations
proved to be equally as effective as
once-daily administrations assessed
according to  markers of bone min-
eral density and bone change.  At
least some patients show improved
compliance with treatment when the
administration which is  felt to be
awkward  has to be carried out on
only one day a week. 
For a long time a preparation
which would improve bone forma-
tion has been anticipated.  Some-
what surprisingly, perhaps, subcuta-
neous parathyroid hormone injected
once daily has proved to be such a
preparation. PTH with only a cou-
ple of hours of effect is benefical to
the bone whereas an ongoing  in-
creased concentration of PTH is
harmful.  A very recent publication
showed that a 1.5-year course of
treatment in postmenopausal
women, who had sustained at least
one osteoporotic vertebral fracture,
increased the mineral density of
lumbar vertebrae by 9-13% and de-
creased the risk of a new vertebral
fracture by 65–69%.  An answer is
being sought at present to the ques-
tion of how this treatment could be
naturally combined with modern
drugs preventing bone loss.  Admin-
istration of parathyroid hormone
for 1–2 years  which is then fol-
lowed up by treatment preventing
bone loss would seem the solution.
Conclusion
Several effective drugs exist today
for the treatment of osteoporosis
and prevention of osteoporotic frac-
tures.  Patients with an existing his-
tory of fractures should be the first
to be included in the management
scheme.  Urgent agreement  needs to
be reached on deciding  who will
give advice on treatment to these
patients – the surgeon involved in
the treatment of the fracture, 
or the GP?
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Summary 
The National Agency for Medicines
(NAM) has issued a new administra-
tive regulation, ”Clinical trials on
medicinal products in human sub-
jects”, which came into force on 1
May 2001. 
The Act and the Decree on med-
ical research were promulgated in
Finland in 1999. This is the first
time in Finland that the establish-
ment, duties and ethical principles of
Ethical Committees have been cov-
ered by legislation: this also includes
issues like the consent of the subject
and the underaged and handicapped
as subjects.  
The EU guidelines on good clini-
cal practice, GCP, were issued in
1997. They include, for instance, a
vocabulary, advice on the content of
a research plan and patient informa-
tion leaflet, and documents neces-
sary for the trials and the safe-keep-
ing of these.  The guidelines can be
found on the Internet pages of the
EMEA www.emea.eu.in/pdfs/hu-
man/ich/013595en.pdf.
Some of the sections which differ
from those in the previous regula-
tion are presented below.
Ethical assessment
Up till now a statement by the
Ethics Committee has been required
to be enclosed with the notification
to the NAM of a planned trial,
whereas from now on it is sufficient
to submit the statement to the
Agency before starting the trial. The
notification of a planned trial can
now be submitted simultaneously to
both the Ethics Committee and
NAM. The NAM has 60 days fol-
lowing submission of the notifica-
tion to request any additional re-
ports necessary.  If there are no re-
quests for further reports within the
prescribed time limit, the trial may
start as soon as the supporting state-
ment of the Ethics Committee is
submitted to the NAM. The re-
searcher should nevertheless be pre-
pared to receive requests for further
reports and suggestions of changes
in the research plan and consent
document from both the Ethics
Committee and the Agency.
Reports of adverse reactions
The legal obligation to notify the
NAM of adverse reactions has been
narrowed and made easier. Previous-
ly, every severe adverse event had 
to be reported to the NAM. Nowa-
days it is sufficient to report adverse
reactions which are both severe and
unexpected.  An adverse reaction
differs from an adverse event in that
an adverse event with a possible
causal relationship with the medici-
nal product is called a reaction. The
due dates of reports have been ex-
tended. Severe, unexpected adverse
reactions which have led to death or
to a life-threatening situation must
be reported to NAM within seven
days. Other severe unexpected ad-
verse reactions must be reported
within 15 days. If the adverse reac-
tion is not both severe and unex-
pected, a reference to it in the report
of the trial results is sufficient.  The
terms ‘severe’ and ‘unexpected’ are
explained at the start of the regula-
tion, where the rest of the terminol-
ogy used is also defined. The reports
should preferably be made in writ-
ing; fax can be used in exceptional
cases, but they should not be made
via e-mail.
A new feature is an annual sum-
mary of suspected severe adverse re-
actions in the course of long-term
trials, including a report on the safe-
ty of  the subjects of the trial.
Other revisions
Definitions of terms used in the reg-
ulation are explained at the begin-
ning. Coherent terminology will
hopefully clarify the content of the
regulation and facilitate the ex-
change of information.
The regulation contains an oblig-
ation for researchers to report  their
trial results within one year of com-
pletion of the trial. If the trial is in-
terrupted prematurely, the reasons
for the interruption and the causes
responsible must be reported to the
NAM within 15 days. The research-
er has an ethical obligation to pub-
lish his or her research results. The
NAM for its part aims to monitor
important information and ensure
that it is not kept secret but is made
available to the authorities and the
entire medical community.
Practical needs are served by de-
tailed instructions regarding exemp-
tion from the processing fee, the
contact person for multicentre stud-
ies, and the start and completion of
trials.  
Where to obtain the regulation?
The regulation is available via the
Internet. The home page of NAM
www.nam.fi has links to the Finnish
and Swedish texts and the unofficial
translation in English. The home
page also contains links to forms for
notifications. Printed English version
of regulation can be ordered by
phone +358 9 4733 4213 in NAM.
New administrative regulation on clinical trials 
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